925-56-4

Upstream product

• 74-90-8 hydrogen cyanide 
• 151-50-8 potassium cyanide 
• 922-67-8 propynoic acid methyl ester 
• 80-63-7 methyl 2-chloroacrylate 
• 143-33-9 sodium cyanide 
• 67-64-1 acetone 
• 79-22-1 methyl chloroformate 
• 2345-56-4 Malonamic acid 
• 107-13-1 acrylonitrile 
• 292638-85-8 acrylic acid methyl ester 
• 114980-39-1 3,3-dimethoxydiazirine 
• 920-37-6 2-Chloroacrylonitrile 
• 75-86-5 2-hydroxy-2-methylpropanenitrile 
• 34937-72-9 Methyl β-chloroacrylate 

Downstream Products

• 97311-73-4 3-Cyan-2-cyclohexylpropansaeure-methylester 
• 97311-72-3 3-Cyan-3-cyclohexylpropansaeure-methylester 
• 127183-76-0 (2α,3α,4α,5α)-(+/-)-3-Methyl 2-phenylmethyl 4-cyano-2-(diphenylphosphinoyl)-5-phenyl-2,3-pyrrolidinedicarboxylate 
• 127183-75-9 (2α,3α,4α,5β)-(+/-)-4-Methyl 2-phenylmethyl 3-cyano-2-(diphenylphosphinoyl)-5-phenyl-2,4-pyrrolidinedicarboxylate 
• 127183-75-9 (2α,3α,4β,5β)-(+/-)-4-Methyl 2-phenylmethyl 3-cyano-2-(diphenylphosphinoyl)-5-phenyl-2,4-pyrrolidinedicarboxylate 
• 196808-10-3 3-[(3aS,4S,6aS)-6a-(tert-Butyl-diphenyl-silanyloxymethyl)-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-yl]-pyrrolidine-2,5-dione 

Relevant academic research and scientific papers

THERAPEUTIC COMPOUNDS AND METHODS OF USE

The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.

Catalytic Hydrocyanation of Activated Terminal Alkynes

A universal, practical and scalable organocatalytic hydrocyanation manifold to provide β-substituted acrylonitriles bearing an electron-withdrawing functionality has been implemented. The catalytic manifold operates under the reactivity generation principle “a good nucleophile generates a strong base”, and it uses 1,4-diazabicyclo[2.2.2]octane (DABCO) as the catalyst, activated terminal alkynes as substrates and acetone cyanohydrin as the cyanide source. The acrylonitriles obtained as E,Z mixtures are straightforwardly resolved by simple flash chromatography delivering the pure isomers in preparative amounts.

Pyrazolopyrimidine derivative, preparation method, pharmaceutical composition and application

The invention discloses a pyrazolopyrimidine derivative, a preparation method, a pharmaceutical composition and application. The invention provides the pyrazolopyrimidine derivative as shown in a formula I and stereoisomer or solvate or pharmaceutically acceptable salts or active metabolite or prodrug thereof. The pyrazolopyrimidine derivative as shown in the formula I has good inhibitory activity on Bruton's tyrosine kinase (Btk) and particularly has good in vitro and in vivo inhibitory activity on growth of tumor cells, and a good marketization prospect is achieved. Please see the formula I in the description.

Evolution of structure and reactivity in a series of iconic carbenes

We present experimental activation parameters for the reactions of six carbenes (CCl2, CClF, CF2, ClCOMe, FCOMe, and (MeO) 2C) with six alkenes (tetramethylethylene, cyclohexene, 1-hexene, methyl acrylate, acrylonitrile, and α-chloroacrylonitrile). Activation energies range from -1 kcal/mol for the addition of CCl2 to tetramethylethylene to 11 kcal/mol for the addition of FCOMe to acrylonitrile. A generally satisfactory analysis of major trends in the evolution of carbenic structure and reactivity is afforded by qualitative applications of frontier molecular orbital theory, although the observed entropies of activation appear to fall in a counterintuitive pattern. An analysis of computed cyclopropanation transition state parameters reveals significant nucleophilic selectivity of (MeO)2C toward α-chloroacrylonitrile.

Highly active phosphine-free carbene ruthenium catalyst for cross-metathesis of acrylonitrile with functionalized olefins

The carbene ruthenium complex [1,3-bis(2,6-dimethylphenyl)-4,5- dihydroimidazol-2-ylidene](C5H5N)2(Cl) 2RuCHPh (8) was prepared by the reaction of [1,3-bis (2,6-dimethylphenyl)-4,5-dihydroimidazol-2-ylidene](PPh3)(Cl) 2RuCHPh (7) with pyridine and used as a highly effective catalyst for the cross-metathesis of acrylonitrile with various functionalized olefins.

Lewis-acid assisted cross metathesis of acrylonitrile with functionalized olefins catalyzed by phosphine-free ruthenium carbene complex

The exchange of the PPh3 ligand in the complex [1,3-bis(2,6-dimethylphenyl)4,5-dihydroimidazol-2-ylidene](PPh 3)-(Cl)2Ru=CHPh (7) for a pyridine ligand at ambient temperature leads to the formation of the stable phosphine-free carbene ruthenium complex [1,3-bis(2,6-dimethylphenyl)4,5-dihydroimidazol-2-ylidene] (C5H5N)2(Cl)2 Ru=CHPh (8). The resulted ruthenium complex exhibits highly catalytic activity for the cross metathesis of acrylonitrile with various functionalized olefins under mild conditions, and its activity can be further improved by the addition of a Lewis acid such as Ti(O′Pr)4. In the mixture products, the Z-isomer predominates. The Royal Society of Chemistry 2005.

A Second Synthesis of D-Apio-β-D-furanosyl Maleimide as a Structural Analogue of Showdomycin

Apioshowdomycin (3-(D-apio-β-D-furanosyl)-1H-pyrrole-2,5-dione, 2) has been prepared as an analogue of the C-nucleoside showdomycin (1) in seven steps, starting from 2,3-O-isopropylidene-D-apio-D-furanose (8). The key step is the addition of a radical gen

Transition-State Structure Variation in the Diels-Alder Reaction from Secondary Deuterium Kinetic Isotope Effects: The Reaction of Nearly Symmetrical Dienes and Dienophiles Is Nearly Synchronous

Secondary deuterium kinetic isotope effects (KIEs) in the reaction of acrylonitrile, fumaronitrile, vinylidene cyanide, dimethyl fumarate and maleate, and methyl trans-β-cyanoacrylate with isoprene were determined by competition with isoprene-d0 (d0), 4,4-dideuterioisoprene (4,4-d2), and 1,1,4,4-tetradeuterioisoprene (d4).The d4 experiment gives the KIE for 1,1-dideuterioisoprene from the KIEs for 4,4-d2.The KIEs for bond making to the β site of acrylonitrile and vinylidene cyanide are much more inverse than those at the α bond making site but are less than the maximum value expected, which indicates an early, unsymmetrical, concerted transition state.The effects wit fumaronitrile are the same for both 1,1- and 4,4-dideuterioisoprene, indicating equivalent effects at both sites and not bonding to the preferred C-1 site of isoprene most of the time.The KIEs with methyl trans-β-cyanoacrylate are inverse at both bond-making sites to the dienophile and both nearly one-third of the maximum value expected.The results with nearly symmetrical addends are not consistent with a two-step reaction, particularly one with the second step being rate determining, or with a concerted reaction with a highly unsymmetrical transition state, but rather with a concerted pathway that is nearly synchronous.The KIEs with methyl fumarate and maleate suggest an unsymmetrical transition state, but they are within experimental error of a symmetrical transition state.